Literature DB >> 18640463

Weight change associated with the use of migraine-preventive medications.

Frederick R Taylor1.   

Abstract

BACKGROUND: Medications administered long term, such as those used for migraine prophylaxis, are often associated with weight change as a side effect. Such effects may compromise general health status, exacerbate coexisting medical conditions, and affect medication adherence. Weight gain should be of particular concern in patients with migraine, as there is evidence that overweight and obese patients with migraine are at risk for an increased frequency and severity of migraine attacks.
OBJECTIVE: This article reviews weight-change data from recent clinical studies of migraine-preventive medications in children, adolescents, and adults with migraine.
METHODS: A PubMed search was conducted for English-language articles published between January 1970 and November 2007. Among the search terms were migraine prevention, migraine prophylaxis, migraine treatment, antidepressant drug, beta-adrenergic-receptor blockers, antiepileptic drug, anticonvulsant drug, weight gain, and weight loss. Studies that reported weight-change data (gain, loss, or neutral) were included. When available, double-blind, placebo-controlled studies were selected for review. Open-label, retrospective or prospective trials may also have been included.
RESULTS: Most of the migraine-preventive medications classified by the United States Headache Consortium as group 1 based on the high level of evidence for their efficacy--for instance, amitriptyline, propranolol, and divalproex sodium-have been associated with varying degrees of weight gain. The exceptions are timolol, which is weight neutral, and topiramate, which is associated with weight loss. Among the drugs that have been associated with weight gain, a higher incidence of weight gain was observed with amitriptyline and divalproex sodium than with propranolol.
CONCLUSION: Weight-change effects require careful consideration when selecting migraine-preventive medications, and weight should be monitored carefully over the course of any migraine treatment plan.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18640463     DOI: 10.1016/j.clinthera.2008.06.005

Source DB:  PubMed          Journal:  Clin Ther        ISSN: 0149-2918            Impact factor:   3.393


  11 in total

Review 1.  The young brain and concussion: imaging as a biomarker for diagnosis and prognosis.

Authors:  Esteban Toledo; Alyssa Lebel; Lino Becerra; Anna Minster; Clas Linnman; Nasim Maleki; David W Dodick; David Borsook
Journal:  Neurosci Biobehav Rev       Date:  2012-03-28       Impact factor: 8.989

Review 2.  Obesity and headache: Part II--potential mechanism and treatment considerations.

Authors:  Nu Cindy Chai; Dale S Bond; Abhay Moghekar; Ann I Scher; B Lee Peterlin
Journal:  Headache       Date:  2014-02-11       Impact factor: 5.887

Review 3.  Dietary considerations in migraine management: does a consistent diet improve migraine?

Authors:  Alan G Finkel; Juanita A Yerry; J Douglas Mann
Journal:  Curr Pain Headache Rep       Date:  2013-11

Review 4.  Headache and obesity in the pediatric population.

Authors:  Christopher B Oakley; Ann I Scher; Ana Recober; B Lee Peterlin
Journal:  Curr Pain Headache Rep       Date:  2014-05

5.  Topiramate in the prevention and treatment of migraine: efficacy, safety and patient preference.

Authors:  Steffen Naegel; Mark Obermann
Journal:  Neuropsychiatr Dis Treat       Date:  2010-02-03       Impact factor: 2.570

Review 6.  Pediatric Obesity Algorithm: A Practical Approach to Obesity Diagnosis and Management.

Authors:  Suzanne E Cuda; Marisa Censani
Journal:  Front Pediatr       Date:  2019-01-23       Impact factor: 3.418

7.  Tolerability of eptinezumab in overweight, obese or type 1 diabetes patients.

Authors:  Brian Baker; Barbara Schaeffler; Joe Hirman; Marcus Hompesch; Susan Pederson; Jeff Smith
Journal:  Endocrinol Diabetes Metab       Date:  2021-02-02

8.  Propranolol for Treatment of Infantile Hemangioma: Efficacy and Effect on Pediatric Growth and Development.

Authors:  Rachel A Giese; Merit Turner; Mario Cleves; J Reed Gardner; Gresham T Richter
Journal:  Int J Pediatr       Date:  2021-04-07

9.  Prophylatic treatment of migraine and migraine clinical variants with topiramate: an update.

Authors:  Sergio Carmona; Osvaldo Bruera
Journal:  Ther Clin Risk Manag       Date:  2009-08-20       Impact factor: 2.423

10.  Metabolic syndrome and migraine.

Authors:  Amit Sachdev; Michael J Marmura
Journal:  Front Neurol       Date:  2012-11-19       Impact factor: 4.003

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.